Marburg Virus Disease
📧 Sign up to get email alerts when something new happens for Marburg Virus Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health [Phase 1]
A Phase 1 randomized, observer-blind, placebo-controlled, dose-escalation trial to evaluate the safety and immunogenicity of the rVSVΔG-MARV…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults [Phase 2]
Phase 2 clinical trial update evaluating safety, tolerability, and immune responses of an investigational monovalent chimpanzee adenoviral v…
-
CLINICAL_TRIALS trial_result · 2025-09-05Clinical Trial Update: Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects [Phase 1]
Phase 1 study evaluating the recombinant VSV-based Marburg virus vaccine candidate PHV01 in healthy adults has completed.
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers [Phase 1]
This update reports the completion of a Phase 1 safety trial evaluating MVA-BN Filo and Ad26.ZEBOV vaccines in healthy volunteers.
-
CLINICAL_TRIALS trial_result · 2025-07-23Clinical Trial Update: Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults [Phase 2]
Phase 2 clinical trial of a monovalent chimpanzee adenoviral-vectored Marburg virus vaccine in healthy adults has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-05-14EMA Authorised: Mvabea (recombinant Modified Vaccinia Ankara Bavarian Nordic Virus encoding the: Ebola virus Zaire (ZEBOV) Mayinga strain glycoprotein (GP); Ebola virus Sudan Gulu strain GP; Ebola virus Taï Forest strain nucleoprotein and the Marburg virus Musoke strain GP) — Janssen-Cilag International N.V.
EMA authorised Mvabea, a recombinant Modified Vaccinia Ankara-based vaccine developed by Janssen-Cilag International N.V., for prevention of…
-
CLINICAL_TRIALS trial_result · 2021-07-23Clinical Trial Update: A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 [Phase 1]
Phase 1 trial evaluating single-dose safety, tolerability, and pharmacokinetics of IV BCX4430 for Marburg Virus Disease has been completed w…
-
CLINICAL_TRIALS trial_result · 2021-01-14Clinical Trial Update: cAd3-Marburg Vaccine in Healthy Adults [Phase 1]
Phase 1 trial of cAd3-Marburg vaccine in healthy adults has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Ebola and Marburg Virus Vaccines [Phase 1]
A Phase 1 trial evaluating Ebola and Marburg virus vaccines has completed. The study was sponsored by the National Institute of Allergy and …
-
CLINICAL_TRIALS trial_result · 2013-01-28Clinical Trial Update: Evaluating an Ebola and a Marburg Vaccine in Uganda [Phase 1]
A Phase 1 trial conducted in Uganda evaluated Ebola and Marburg vaccines. The study is completed.